Biostem Technologies (BSEM) investor relations material

Strategic updates and financial performance

• Announced Q1 revenue of $6.1 million with a 61% margin and $13.7 million in cash and equivalents.

• Issued first full-year revenue guidance for 2026 at $25–$29 million.

• Completed KPMG audits for 2024 and 2025 and confidentially filed Form 10 for Nasdaq uplisting.

• Received first analyst coverage with a $7 price target and strengthened the balance sheet by retiring outstanding debt.

BioTissue acquisition and integration

• Closed acquisition of BioTissue Surgical assets in January, expanding into orthopedics, urology, spine, women's health, and foot and ankle.

• Acquisition valued at 0.8x revenue, bringing $29 million in 2025 revenue and $5 million EBITDA.

• Added 25 direct sales reps, now grown to 35, forming the first national sales team.

• Diversified payer mix to 90% commercial, reducing reliance on Medicare.

Market opportunity and product portfolio

• Addressable U.S. market expanded from $15 billion to $23 billion post-acquisition.

• Portfolio includes six perinatal-derived allograft brands and 68 issued U.S. patents.

• 510(k) approval for a key product expected in 2026.

• Plan to expand direct sales team to 40+ by year-end and increase GPO account activations.